Department of Endocrinology and Rheumatology Immunology, 3201 Hospital, Hanzhong, China.
J Clin Lab Anal. 2021 Nov;35(11):e23924. doi: 10.1002/jcla.23924. Epub 2021 Sep 26.
Long noncoding RNA PCAT1 (lnc-PCAT1) involves in the proliferation and drug sensitivity of multiple myeloma (MM), while its prognostic role in MM patients is still obscure. This study aimed to explore the association of lnc-PCAT1 with MM risk, clinical characteristics, treatment response, progression-free survival (PFS), and overall survival (OS).
A total of 83 symptomatic MM patients were enrolled in this study. Additionally, 30 healthy bone marrow donors as health controls were also recruited. Bone marrow plasma cell samples of MM patients and health donors were collected. Lnc-PCAT1 in bone marrow plasma cells was detected by reverse transcription-quantitative polymerase chain reaction.
Lnc-PCAT1 was increased in MM patients than in health donors (p < 0.001), and receiver operating characteristic (ROC) curve showed that lnc-PCAT1 had excellent capability of discriminating MM patients from health donors (area under curve: 0.932, 95% confidence interval: 0.889-0.976). In MM patients, lnc-PCAT1 was correlated with bone lesion (p = 0.024), higher β -MG (p = 0.005), LDH (p = 0.037), and presence of Del (17p) (p = 0.029). Lnc-PCAT1 was also associated with poor ISS stage (p = 0.013) and R-ISS stage (p = 0.005). Besides, lnc-PCAT1 was reduced after treatment (p < 0.001); meanwhile, lnc-PCAT1 before treatment was correlated with lower CR (p = 0.046) but not ORR (p = 0.185). Additionally, lnc-PCAT1 after treatment was associated with lower CR (p = 0.003) and ORR (p = 0.010). Furthermore, baseline Inc-PCAT1 high and Inc-PCAT1 increase after treatment were correlated with worse PFS and OS (all p < 0.05).
Lnc-PCAT1 dysregulation serves as a biomarker for diagnosis and prognosis for MM.
长链非编码 RNA PCAT1（lnc-PCAT1）参与多发性骨髓瘤（MM）的增殖和药物敏感性，但其在 MM 患者中的预后作用尚不清楚。本研究旨在探讨 lnc-PCAT1 与 MM 风险、临床特征、治疗反应、无进展生存期（PFS）和总生存期（OS）的关系。
本研究共纳入 83 例有症状的 MM 患者。此外，还招募了 30 名健康骨髓供者作为健康对照。采集 MM 患者和健康供者的骨髓浆细胞样本。采用逆转录定量聚合酶链反应检测骨髓浆细胞中的 lnc-PCAT1。
lnc-PCAT1 在 MM 患者中的表达高于健康供者（p<0.001），ROC 曲线显示 lnc-PCAT1 具有区分 MM 患者和健康供者的优异能力（曲线下面积：0.932，95%置信区间：0.889-0.976）。在 MM 患者中，lnc-PCAT1 与骨病变相关（p=0.024），与更高的β-MG（p=0.005）、LDH（p=0.037）和 Del（17p）的存在相关（p=0.029）。lnc-PCAT1 也与较差的 ISS 分期（p=0.013）和 R-ISS 分期（p=0.005）相关。此外，治疗后 lnc-PCAT1 降低（p<0.001）；同时，治疗前 lnc-PCAT1 与较低的完全缓解率（CR）相关（p=0.046），但与总缓解率（ORR）无关（p=0.185）。此外，治疗后 lnc-PCAT1 与较低的 CR（p=0.003）和 ORR（p=0.010）相关。此外，基线 lnc-PCAT1 升高和治疗后 lnc-PCAT1 升高与较差的 PFS 和 OS 相关（均 p<0.05）。
lnc-PCAT1 失调可作为 MM 的诊断和预后生物标志物。
